Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07085468 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3549492 in Healthy Weight Adult Participants
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT07085468 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 1 participants.
The verdict
NCT07085468, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in adult participants with a healthy body max index (BMI) of 22 to 25 kilograms per square meter (kg/m2). Participation in the study will last about 13 months.
Interventions
- DRUG Placebo
- DRUG LY3549492
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2025-07-21 |
| Est. Completion | 2025-08-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07085468
The ClinicalTrials.gov registry entry for NCT07085468 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07085468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07085468 about?
NCT07085468 is a clinical study titled "A Study of LY3549492 in Healthy Weight Adult Participants". The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in adult participants with a healthy body max index (BMI) of 22 to 25 kilograms per square meter (kg/m2). Participation in the study will last about 13 months.
What is the current status of trial NCT07085468?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2025-07-21. Estimated completion is 2025-08-14.
What interventions are being tested in trial NCT07085468?
The interventions under investigation include: Placebo (DRUG), LY3549492 (DRUG).
Who is sponsoring clinical trial NCT07085468?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.